Clément Vidal Is Appointed New CEO at eCential

eCential Robotics is pleased to announce the appointment of Clément Vidal as its new Chief Executive Officer. Clément Vidal, an Ecole Polytechnique and Stanford University graduate, has 20 years of experience in the Pharmaceutical and Medical Device industry, especially as CEO of surgical robotics company Endocontrol. Clément will be succeeding Stéphane Lavallée, founder, who will now serve as non-executive Chairman of the Board.

“Through his excellent management of key strategic development programs within eCential Robotics, Clément has proven himself to be not only an amazing leader, but a visionary with a solid understanding of the surgical robotics market,” said Lavallée. “I am most confident that Clément will succeed in taking the company to the next level, with the same passion and commitment to innovation that has always been our hallmark.”

A unique company and product
Founded in 2009, eCential Robotics started its journey with only a handful of visionary engineers to invent the surgical technologies of the future. Working hand-in-hand with leading surgeons around the world, the company developed the first open, unified yet modular and scalable 2D/3D imaging, navigation and robotic guidance system for spine surgery. Recognized with several innovation awards, the company attracted strong funding partners, leading to an initial limited release in Europe with over 10 systems sold and installed. Having received FDA clearance for its platform, the team is now gearing up to develop its activities in the US.

Accelerating activities with implant partners and US customers

“I am honored to take on the role of CEO at such an exciting time for the company,” said Vidal. “The team recently demonstrated its ability to successfully partner with MedTech companies, as well as commercialize our proprietary robotics system by signing a supply contract with a major healthcare group in the United States.”

Under Clément Vidal’s leadership, eCential Robotics will continue to build a culture of excellence, enhance the company’s product portfolio roadmap, develop its commercial activities in the US as well as partner internationally with implant manufacturers, tech companies and research labs to expand the range of Applications available on its unique Open eCential Platform.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”